Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Takeda Pharmaceutical ADR Rep 0.5 Ord Shs V.TAK


Primary Symbol: TAK

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.


NYSE:TAK - Post by User

Post by gold_strikeon Jan 15, 2015 1:51pm
377 Views
Post# 23324175

share consolidation

share consolidation


Can't tell if this is trading since the R/S



Taku Gold undertakes 10:1 Consolidation, Shares for Debt Settlement and Commences Trading on the Canadian Securities Exchange

Vancouver, B.C., January 5, 2015 - Taku Gold Corp. (the "Company") (CSE: TAK)

announces that further to the Company’s news release dated December 24, 2014, the Company is undertaking a 10:1 Consolidation and Shares for Debt Settlement in conjunction with listing on the Canadian Securities Exchange ("CSE"). The Company is delisting its common shares from the TSX Venture Exchange at the close of business day on January 5, 2015 and will commence trading its common shares on post-consolidated basis on CSE on January 6, 2015. The Company’s name and trading symbol will remain the same. The new CUSIP number will be 874072200.

The Company concurrently will undertake shares-for-debt settlements in the aggregate amount of $158,000 as owed to four creditors, by the issuance of an aggregate of 1,580,000 post-consolidated common shares of the Company at $0.10 per common share. The common shares issued pursuant to this debt settlement will be subject to a hold period expiring May 6, 2015.

On Behalf of the Board of Taku Gold Corp.,

Zachery Dingsdale

Bullboard Posts